Buckhound: The increased prevalence of type 2 diabetes mellitus (DM) is an important public health problem. The number of patients with DM worldwide is estimated to rise to 366 million by the year 2030. In general, individuals with DM have more severe and diffuse atherosclerotic disease, which accounts for the significantly higher incidence of cardiovascular events in their native coronary, cerebrovascular, and peripheral arteries. Objective: The aim of this study was to assess the short and mid-term clinical outcomes in type 2 diabetic patients with stable coronary artery disease treated with 2nd generation drug eluting stents. Patients and Methods: This prospective observational study included a total of 100 type 2 DM-CAD patients, attending at Department of Cardiology, Tanta University Hospitals. This study was conducted between January 2018 till January 2019. Assessment of the mid and short-term clinical outcomes in patients was done. Results: Non-significant difference as regards age, sex and family history (p > 0.05) was found. Non-significant difference as regards height, weight, BMI, HTN and smoking (p > 0.05) was found. Significant increase in inverted T wave in Major Adverse Cardiovascular Events (MACE) group; compared to normal group; with significant statistical difference (p = 0.015). Non-significant difference as regards creatinine, ST elevation, ST depression, pathological Q, LBBB and RBBB (p > 0.05) were found. Highly significant decrease in EF in MACE group; compared to normal group; with highly significant statistical difference (p < 0.01) were found. Conclusion: Diabetes mellitus is a condition in which the use of 2nd generation zotarolimus-eluting stents is preferable, in order to reduce the incidence of MACE adverse events.